Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for ci 1033 (compound)
Most Correlated Studies
- L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
- L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
- L1000 CMAP - Hepatocellular carcinoma HEPG2 cells treated with small molecule perturbagens
- L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
- L1000 CMAP - Prostate cancer LNCAP cells treated with small molecule perturbagens
Most Relevant Literature
- A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-103…
- Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancer.
- Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previous…
- The pan-erbB tyrosine kinase inhibitor CI-1033 inhibits human esophageal cancer cells in vitro and i…
- The pan-ErbB receptor tyrosine kinase inhibitor canertinib induces ErbB-independent apoptosis in hum…
Most Relevant Clinical Trials
- PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy…
- A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer
- A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small …
- 3T MRI CIED Post-Approval Study
- Topical Sunscreen in Preventing Skin Rash in Patients Receiving Drugs Such as Erlotinib or Cetuximab…
